Volume 20, Issue 8 p. 958-963
Research Article

Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease

William G. Ondo MD

Corresponding Author

William G. Ondo MD

Department of Neurology, Baylor College of Medicine, Houston, Texas, USA

Baylor College of Medicine, Department of Neurology, 6550 Fannin, Suite 1801, Houston, Texas 77030Search for more papers by this author
Ron Tintner MD

Ron Tintner MD

Department of Neurology, Baylor College of Medicine, Houston, Texas, USA

Search for more papers by this author
Kevin Dat Voung MA

Kevin Dat Voung MA

Department of Neurology, Baylor College of Medicine, Houston, Texas, USA

Search for more papers by this author
Dejian Lai PhD

Dejian Lai PhD

Division of Biostatistics, School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas, USA

Search for more papers by this author
George Ringholz MD, PhD

George Ringholz MD, PhD

Emory University School of Medicine, Department of Neurology, Atlanta, Georgia, USA

Search for more papers by this author
First published: 30 March 2005
Citations: 226

Abstract

We completed a single site, double-blind, placebo-controlled, parallel design study of quetiapine for hallucinations in PD. Thirty-one subjects with PD and prominent visual hallucinations and Mini-Mental State Examination score >21 were randomly assigned in a 2:1 drug to placebo ratio, up to 200 mg daily of quetiapine or matching placebo given in two doses. They were seen at 3 weeks (100 mg/day) and 12 weeks (200 mg/day, with optional dose reduction). Evaluation included the Unified Parkinson's Disease Rating Scale (UPDRS), the Baylor PD Hallucination Questionnaire, and a battery of neuropsychological tests. The demographics between subjects randomized to drug (n = 21) vs. placebo (n = 10) were similar. The final dose of active drug was 200 (n = 11), 150 (n = 2), 100 (n = 3), and 75 (n = 1) mg per day. All placebo subjects were on the equivalent of 200 mg per day. The UPDRS Activities of Daily Living and Motor scores did not significantly change compared to placebo. Compared to placebo, there were no significant changes in our hallucination questionnaire, the Brief Psychiatric Rating Scale (BPRS), or question 12 (hallucination item) of the BPRS. There were no significant changes on any of the neuropsychological measures. Adverse events on drug included sedation (n = 9), but no drug-related adverse events precipitated discontinuation and none were rated as serious. Quetiapine, up to 200 mg daily, was well tolerated and did not worsen UPDRS scores; however, there was no significant improvement in psychosis rating scales compared to placebo. Larger doses of drug and greater sample sizes might be considered in future studies. © 2005 Movement Disorder Society